VOTING RIGHTS AND CAPITAL

Edinburgh, UK, February 28, 2008: Ardana plc (LSE:ARA), in conformity with the Transparency Directive’s transitional provision 6, today notifies the market of the following:

As at 28 February 2008, the issued share capital and voting rights of Ardana plc are as follows:

Ardana plc’s capital consists of 65,511,729 ordinary 1p shares with voting rights attached of one vote per ordinary share of which 12,681 ordinary shares are held in Treasury.

Therefore, the total number of voting rights in Ardana plc is 65,499,048.

The above figure (65,499,048) may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, Ardana plc under the FSA’s Disclosure and Transparency Rules.

For more information contact:

Ardana plc (LSE: ARA) is an emerging pharmaceutical company focused on the discovery, development and marketing of innovative products to improve human reproductive health, a $25.5 billion market.  

Ardana’s lead products are summarised below:

• Teverelix LA, in development for three initial indications (prostate cancer, benign prostatic hyperplasia and endometriosis);
• ARD-0705 a growth hormone secretagogue in Phase III for the diagnosis of growth hormone deficiency in adults;
• Testosterone Cream, a transdermal testosterone delivery system in development for the treatment of male hypogonadism, in Phase III trials;
• Emselex®, a once a day treatment for the symptoms of overactive bladder syndrome, which Ardana has exclusive UK marketing and promotion rights and is being distributed in collaboration with Novartis UK Limited;
• StriantTM SR, a testosterone replacement therapy that has been launched by Ardana through its own sales force in the UK and through marketing partners in certain European countries, as a treatment for men with confirmed hypogonadism; and
• InvicorpTM, an injectable combination drug treatment for erectile dysfunction, for which Ardana has marketing and manufacturing rights in Europe and has been launched in Denmark.

For further information please see www.ardana.co.uk

back to top